What is thalassemia (a genetic disorder affecting hemoglobin production)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Thalassemia is a genetic disorder that affects the production of hemoglobin, a protein in red blood cells that carries oxygen to the body's tissues [ 1 ].

Key Characteristics

  • It is characterized by a severe reduction or absent production of the β-globin chain constituent of hemoglobin (Hb) A [ 1 ]
  • This results in ineffective erythropoiesis caused by an excess of α-globin chains and profound anemia that is life-threatening from ≈1 to 2 years of age [ 1 ]
  • Blood transfusions are required lifelong, and iron chelation treatment is necessary to prevent or reverse iron-related complications [ 1 ]

Treatment and Management

  • Regular blood transfusions are typically given every 2-4 weeks for patients with beta-thalassemia major [ 1 ]
  • Iron chelation therapy, such as deferasirox (Exjade) or deferoxamine (Desferal), is also necessary to remove excess iron from the body [ 1 ]
  • Folic acid supplements may be prescribed to help increase red blood cell production [ 1 ]
  • In some cases, bone marrow transplantation may be considered as a treatment option [ 1 ]

Monitoring and Prevention

  • Regular medical check-ups are essential to monitor the condition and adjust the treatment plan as needed [ 1 ]
  • Genetic counseling is recommended for individuals with a family history of thalassemia to discuss the risk of passing the disorder to their children [ 1 ]
  • Pregnant women with thalassemia should receive close medical monitoring, including regular blood transfusions and iron chelation therapy, to ensure the best possible outcomes for both the mother and the baby [ 1 ]

From the Research

Definition and Causes of Thalassemia

  • Thalassemia is a group of autosomal recessive hemoglobinopathies affecting the production of normal alpha- or beta-globin chains that comprise hemoglobin 2.
  • It is caused by a defect in one or more of the genes that code for alpha- or beta-globin chains, resulting in abnormal hemoglobin production 3.
  • The disorder is characterized by ineffective production of alpha- or beta-globin chains, leading to ineffective erythropoiesis, premature red blood cell destruction, and anemia 2.

Types and Symptoms of Thalassemia

  • Thalassemia can be classified into different types, including alpha-thalassemia and beta-thalassemia, each with varying degrees of severity 2, 4.
  • Alpha-thalassemia major can result in hydrops fetalis and is often fatal at birth, while beta-thalassemia major requires lifelong transfusions starting in early childhood 2.
  • Thalassemia intermedia has variable presentations, with mild forms requiring only monitoring and more severe forms leading to symptomatic anemia and requiring transfusion 2.

Treatment and Complications of Thalassemia

  • Treatment of thalassemia includes transfusions, iron chelation therapy, hydroxyurea, hematopoietic stem cell transplantation, and luspatercept 2.
  • Complications of thalassemia arise from bone marrow expansion, extramedullary hematopoiesis, and iron deposition in peripheral tissues, affecting the skeletal system, endocrine organs, heart, and liver 2.
  • Splenectomy may be considered as a treatment option for people with thalassemia major or intermedia, although the evidence is limited and of low quality 5.

Impact on Families and Caregivers

  • Thalassemia can have a significant impact on families and caregivers, causing mental, social, financial, and physical burdens 6.
  • Repeated blood transfusions and treatment complications can lead to tissue damage, morbidity, and fatal clinical outcomes, highlighting the need for effective management and support 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Alpha- and Beta-thalassemia: Rapid Evidence Review.

American family physician, 2022

Research

Thalassemia, a human blood disorder.

Brazilian journal of biology = Revista brasleira de biologia, 2021

Research

Splenectomy for people with thalassaemia major or intermedia.

The Cochrane database of systematic reviews, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.